These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27862475)

  • 21. Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Molina-Molina M; Acosta O; Bollo E; Castillo D; Fernández-Fabrellas E; Rodríguez-Portal JA; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2017 May; 53(5):263-269. PubMed ID: 28292522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic advances in idiopathic pulmonary fibrosis.
    Fraser E; Hoyles RK
    Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Anderson A; Shifren A; Nathan SD
    Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Idiopathic Pulmonary Fibrosis.
    Pleasants R; Tighe RM
    Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
    [No Abstract]   [Full Text] [Related]  

  • 26. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
    Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
    Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
    Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idiopathic pulmonary fibrosis: an update.
    Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
    Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.
    King CS; Nathan SD
    Curr Opin Pulm Med; 2015 Sep; 21(5):479-89. PubMed ID: 26164298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
    Antoniou K; Kamekis A; Symvoulakis EK; Kokosi M; Swigris JJ
    Curr Opin Pulm Med; 2020 Sep; 26(5):457-463. PubMed ID: 32701673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.